Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822302 | 0.83 | ALDH1A1 (0.46) | LPOLMNACYP1A2ALDH1A1RGS12 | |
| SCHEMBL25254399 | 0.81 | ALDH1A1 (0.39) | LPOLMNACYP1A2ALDH1A1RGS12 | |
| SCHEMBL402733 | 0.78 | MGAM (0.42) | LPOLMNACYP1A2ALDH1A1RGS12 | |
| SCHEMBL18366656 | 0.76 | TNF (0.40) | ALDH1A1RGS12MAPTPOLB | |
| SCHEMBL368414 | 0.74 | NAMPT (0.44) | LPOLMNAALDH1A1MAPTHTT | |
| SCHEMBL20267842 | 0.73 | JMJD6 (0.47) | LMNAALDH1A1RGS12MAPTHTT | |
| 1-Methylimidazole SCHEMBL8045723 | 0.73 | TBXAS1 (0.45) | CYP1A2ALDH1A1RGS12MAPTNAMPT | |
| SCHEMBL12094827 | 0.73 | NAMPT (0.43) | LPOLMNAALDH1A1MAPTHTT | |
| SCHEMBL29441633 | 0.72 | ALDH1A1 (0.41) | CYP1A2ALDH1A1RGS12MAPTJMJD6 | |
| SCHEMBL5604635 | 0.72 | TSHR (0.49) | LPOLMNAALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624010-B2 | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway | AC IMMUNE SA (CH) | 2026-05-12 | — | — | US | disclosed |
| EP-4168395-B1 | DIHYDROOXAZOLE AND THIOUREA OR UREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2023-08-10 | — | — | US | disclosed |
| EP-4168395-A1 | DIHYDROOXAZOLE AND THIOUREA OR UREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC Immune SA (CH) | 2023-04-26 | — | — | EP | disclosed |
| CN-115768754-A | Dihydrooxazole and thiourea or urea derivatives that modulate NLRP3 inflammasome pathways | AC免疫有限公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2021255279-A1 | D I H YD ROOXAZO LE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2021-12-23 | — | — | WO | disclosed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624010-B2 | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway | NOD1, NLRP3, NLRP1 | LPO 2738/4885LMNA 2131/4885CYP1A2 550/4885 |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | LPO 4637/4885LMNA 2076/4885CYP1A2 2921/4885 |
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NOD1, NLRP1 | LPO 3599/4885LMNA 4053/4885CYP1A2 954/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | LPO 4637/4885LMNA 2076/4885CYP1A2 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.